Form 4: BioLargo Director Jack Strommen Granted 75,000 Stock Options as Compensation

BioLargo, Inc. Director Jack B. Strommen received 75,000 options to purchase common stock at an exercise price of $0.20 as compensation for board services.

Summary

• Director Jack B. Strommen of BioLargo, Inc. (BLGO) was granted 75,000 options to purchase common stock.
• The options have an exercise price of $0.20 per share.
• The grant date and exercisable date for these options is June 30, 2025, with an expiration date of June 30, 2035.
• These options were issued as payment for $15,000 in fees due to Mr. Strommen for his services on the board of directors for the most recently completed quarterly period.
• The grant was made pursuant to the Issuer's 2024 Equity Incentive Plan.
• Following this transaction, Mr. Strommen beneficially owns 2,189,886 derivative securities.

Sentiment

Score: 6

Explanation: The document reports a routine compensation event for a director, which is generally a neutral to slightly positive signal as it aligns interests. There are no significant positive or negative financial or operational disclosures.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The compensation is part of a formal 2024 Equity Incentive Plan, indicating structured governance around executive and director remuneration.

Risks

• Future exercise of the 75,000 options could lead to minor dilution for existing shareholders.
• The value of the options is dependent on the future stock price of BioLargo, Inc., exposing the director to market volatility.

Future Outlook

The document primarily details a past compensation event and does not provide explicit forward-looking statements or guidance regarding company performance or strategic direction, beyond the future exercisability and expiration of the granted options.

Management Comments

• This Option was issued to Reporting Person as payment for $15,000 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.

Industry Context

The grant of stock options to a director as compensation for board services is a common practice across various industries, particularly in publicly traded companies. This method of compensation is often used to align the interests of board members with those of shareholders, encouraging long-term value creation.

Comparison to Industry Standards

• Compensating directors with equity, such as stock options, is a standard practice in corporate governance across industries, including biotechnology and environmental technology sectors where BioLargo operates.
• The specific value of the options granted ($15,000 in fees for 75,000 options at a $0.20 exercise price) would typically be benchmarked against director compensation packages at companies of similar market capitalization, revenue, and complexity within the industry. Without specific comparable data, it is noted as a standard form of compensation.

Corporate Governance

Related Party Transactions

• The issuance of 75,000 options to Director Jack B. Strommen as payment for $15,000 in board fees constitutes a related party transaction, which is a standard form of compensation for directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon option exercise, but also improved alignment of director's interests with long-term shareholder value.
• Management/Directors: Jack B. Strommen receives equity-based compensation, linking his financial incentives directly to the company's stock performance.

Next Steps

• The director may exercise the granted options at any time between June 30, 2025, and June 30, 2035, assuming the stock price is above the exercise price of $0.20.

Key Dates

Keywords

BioLargo, BLGO, SEC Form 4, insider transaction, stock options, director compensation, equity incentive plan, corporate governance, executive compensation